1.Homozygous LPL p.Gly188Glu Mutation in a Mexican Girl With Lipoprotein Lipase Deficiency.
Ana Gabriela COLIMA FAUSTO ; Juan Ramón GONZÁLEZ GARCÍA ; Teresita De Jesús HERNÁNDEZ FLORES ; Norma Alejandra VÁZQUEZ CÁRDENAS ; Nery Eduardo SOLÍS PERALES ; María Teresa MAGAÑA TORRES
Annals of Laboratory Medicine 2017;37(4):355-358
No abstract available.
Female*
;
Humans
;
Hyperlipoproteinemia Type I*
;
Lipoprotein Lipase*
;
Lipoproteins*
2.Homozygous LPL p.Gly188Glu Mutation in a Mexican Girl With Lipoprotein Lipase Deficiency.
Ana Gabriela COLIMA FAUSTO ; Juan Ramón GONZÁLEZ GARCÍA ; Teresita De Jesús HERNÁNDEZ FLORES ; Norma Alejandra VÁZQUEZ CÁRDENAS ; Nery Eduardo SOLÍS PERALES ; María Teresa MAGAÑA TORRES
Annals of Laboratory Medicine 2017;37(4):355-358
No abstract available.
Female*
;
Humans
;
Hyperlipoproteinemia Type I*
;
Lipoprotein Lipase*
;
Lipoproteins*
3.A Case of Lipoprotein Lipase Deficiency inan Infant with Recurrent Pancreatitis.
Hae Jin PARK ; Byeong Sam CHOI ; Hye Ran YANG ; Ju Young CHANG ; Jae Sung KO ; Choong Ho SHIN ; Sei Won YANG ; Jeong Kee SEO
Korean Journal of Pediatric Gastroenterology and Nutrition 2009;12(1):79-83
Familial chylomicronemia syndrome is a rare disorder characterized by severe hypertriglyceridemia and fasting chylomicronemia. Causes of the syndrome include lipoprotein lipase (LPL) deficiency, apolipoprotein C-II deficiency, or the presence of inhibitors to LPL. We managed a 3-month-old girl who had recurrent acute pancreatitis caused by chylomicronemia. We report the first case of familial chylomicronemia in Korea caused by LPL deficiency in an infant with recurrent acute pancreatitis.
Fasting
;
Humans
;
Hyperlipoproteinemia Type I
;
Hypertriglyceridemia
;
Infant
;
Korea
;
Lipoprotein Lipase
;
Lipoproteins
;
Pancreatitis
4.A case of neonatal-onset type I hyperlipoproteinemia with bloody ascites.
Yuan-Yuan CHEN ; Li-Yuan HU ; Ke ZHANG ; Xue-Ping ZHANG ; Yun CAO ; Lin YANG ; Bing-Bing WU ; Wen-Hao ZHOU ; Jin WANG
Chinese Journal of Contemporary Pediatrics 2023;25(12):1293-1298
This report presents a case of a male infant, aged 32 days, who was admitted to the hospital due to 2 days of bloody stools and 1 day of fever. Upon admission, venous blood samples were collected, which appeared pink. Blood biochemistry tests revealed elevated levels of triglycerides and total cholesterol. The familial whole genome sequencing revealed a compound heterozygous variation in the <i>LPLi> gene, with one variation inherited from the father and the other from the mother. The patient was diagnosed with lipoprotein lipase deficiency-related hyperlipoproteinemia. Acute symptoms including bloody stools, fever, and bloody ascites led to the consideration of acute pancreatitis, and the treatment involved fasting, plasma exchange, and whole blood exchange. Following the definitive diagnosis based on the genetic results, the patient was given a low-fat diet and received treatment with fat-soluble vitamins and trace elements, as well as adjustments to the feeding plan. After a 4-week hospitalization, the patient's condition improved and he was discharged. Follow-up showed a decrease in triglycerides and total cholesterol levels. At the age of 1 year, the patient's growth and psychomotor development were normal. This article emphasizes the multidisciplinary diagnosis and treatment of familial hyperlipoproteinemia presenting with symptoms suggestive of acute pancreatitis, including bloody ascites, in the neonatal period.
Humans
;
Infant
;
Male
;
Acute Disease
;
Ascites
;
Cholesterol
;
Hyperlipoproteinemia Type I/genetics*
;
Hyperlipoproteinemias
;
Lipoprotein Lipase/genetics*
;
Pancreatitis
;
Triglycerides
5.New Drugs for Treating Dyslipidemia: Beyond Statins.
Diabetes & Metabolism Journal 2015;39(2):87-94
Statins have been shown to be very effective and safe in numerous randomized clinical trials, and became the implacable first-line treatment against atherogenic dyslipidemia. However, even with optimal statin treatment, 60% to 80% of residual cardiovascular risk still exists. The patients with familial hypercholesterolemia which results in extremely high level of low density lipoprotein cholesterol (LDL-C) level and the patients who are intolerant or unresponsive to statins are the other hurdles of statin treatment. Recently, new classes of lipid-lowering drugs have been developed and some of them are available for the clinical practice. The pro-protein convertase subtilisin/kexintype 9 (PCSK9) inhibitor increases the expression of low density lipoprotein (LDL) receptor in hepatocytes by enhancing LDL receptor recycling. The microsomal triglyceride transport protein (MTP) inhibitor and antisense oligonucleotide against apolipoprotein B (ApoB) reduce the ApoB containing lipoprotein by blocking the hepatic very low density lipoprotein synthesis pathway. The apolipoprotein A1 (ApoA1) mimetics pursuing the beneficial effect of high density lipoprotein cholesterol and can reverse the course of atherosclerosis. ApoA1 mimetics had many controversial clinical data and need more validation in humans. The PCSK9 inhibitor recently showed promising results of significant LDL-C lowering in familial hypercholesterolemia (FH) patients from the long-term phase III trials. The MTP inhibitor and antisesnse oligonucleotide against ApoB were approved for the treatment of homozygous FH but still needs more consolidated evidences about hepatic safety such as hepatosteatosis. We would discuss the benefits and concerns of these new lipid-lowering drugs anticipating additional benefits beyond statin treatment.
Apolipoprotein A-I
;
Apolipoproteins
;
Apolipoproteins B
;
Atherosclerosis
;
Cholesterol, HDL
;
Cholesterol, LDL
;
Dyslipidemias*
;
Hepatocytes
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
;
Hyperlipoproteinemia Type II
;
Lipoproteins
;
Receptors, LDL
;
Recycling
;
Triglycerides
6.Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Korean Circulation Journal 2018;48(12):1097-1119
Although elevated serum low-density lipoprotein-cholesterol (LDL-C) is without any doubts accepted as an important risk factor for cardiovascular disease (CVD), the role of elevated triglycerides (TGs)-rich lipoproteins as an independent risk factor has until recently been quite controversial. Recent data strongly suggest that elevated TG-rich lipoproteins are an independent risk factor for CVD and that therapeutic targeting of them could possibly provide further benefit in reducing CVD morbidity, events and mortality, apart from LDL-C lowering. Today elevated TGs are treated with lifestyle interventions, and with fibrates which could be combined with omega-3 fatty acids. There are also some new drugs. Volanesorsen, is an antisense oligonucleotid that inhibits the production of the Apo C-III which is crucial in regulating TGs metabolism because it inhibits lipoprotein lipase (LPL) and hepatic lipase activity but also hepatic uptake of TGs-rich particles. Evinacumab is a monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3) and it seems that it can substantially lower elevated TGs levels because ANGPTL3 also regulates TGs metabolism. Pemafibrate is a selective peroxisome proliferator-activated receptor alpha modulator which also decreases TGs, and improves other lipid parameters. It seems that it also has some other possible antiatherogenic effects. Alipogene tiparvovec is a nonreplicating adeno-associated viral vector that delivers copies of the LPL gene to muscle tissue which accelerates the clearance of TG-rich lipoproteins thus decreasing extremely high TGs levels. Pradigastat is a novel diacylglycerol acyltransferase 1 inhibitor which substantially reduces extremely high TGs levels and appears to be promising in treatment of the rare familial chylomicronemia syndrome.
Apolipoprotein C-III
;
Cardiovascular Diseases
;
Diacylglycerol O-Acyltransferase
;
Fatty Acids, Omega-3
;
Fibric Acids
;
Hyperlipoproteinemia Type I
;
Life Style
;
Lipase
;
Lipoprotein Lipase
;
Lipoproteins
;
Metabolism
;
Mortality
;
PPAR alpha
;
Risk Factors
;
Triglycerides
7.Mutation screening and functional analysis of low density lipoprotein receptor in a familial hypercholesterolemia family.
Xiao-huan CHENG ; Fang ZHENG ; Xin ZHOU ; Chen-ling XIONG ; Junfa DING ; Yong-mei CHEN
Chinese Journal of Medical Genetics 2008;25(1):55-58
OBJECTIVETo screen the mutations of the low density lipoprotein receptor (LDLR) gene in a familial hypercholesterolemia (FH) family, and analyze the LDL-uptaking function of LDLR on lymphocytes of patients.
METHODSGenomic DNA was extracted from four affected members in a Chinese FH family. The presence of apoB100 gene R3500Q mutation which results in familial defective apolipoprotein B100 (FDB) was excluded first. Fragments of the LDLR gene were amplified by touch-down polymerase chain reaction (Touch-down PCR) and analyzed by single-strand conformational polymorphism (SSCP). The suspect fragments of the LDLR gene were cloned and sequenced. Furthermore, the lymphocytes bounded with fluorescent-labeled LDL (DiI-LDL) were measured by fluorescence flow cytometry.
RESULTSA nonsense mutation was identified in exon 10 of LDLR gene. This mutation gave rise to a premature stop codon (W462X), resulting in the absence of most of the LDLR domains. It was detected in all the affected members of the FH family. The ratios of functional LDLR in lymphocytes from patients and normal controls were 63.7% and 77.3% respectively. As a result, the activity of the functional LDLR in patients was just 82.4% of that in the normal controls.
CONCLUSIONIt is possible that the W462X mutation of LDLR gene is the main cause for the disease in this family.
Adult ; Apolipoprotein B-100 ; genetics ; Base Sequence ; Case-Control Studies ; DNA Mutational Analysis ; Deoxyribonuclease I ; metabolism ; Exons ; genetics ; Female ; Flow Cytometry ; Humans ; Hyperlipoproteinemia Type II ; genetics ; metabolism ; pathology ; Lipoproteins, LDL ; metabolism ; Lymphocytes ; metabolism ; Male ; Middle Aged ; Mutation ; Pedigree ; Receptors, LDL ; genetics ; metabolism
8.Gestational hyperlipidemia and acute pancreatitis with underlying partial lipoprotein lipase deficiency and apolipoprotein E3/E2 genotype.
Dong Hee HAN ; In Ho MOH ; Doo Man KIM ; Sung Hee IHM ; Moon Gi CHOI ; Hyung Joon YOO ; Eun Gyoung HONG
The Korean Journal of Internal Medicine 2013;28(5):609-613
We report the case of a patient who experienced extreme recurrent gestational hyperlipidemia. She was diagnosed with partial lipoprotein lipase (LPL) deficiency but without an associated LPL gene mutation in the presence of the apolipoprotein E3/2 genotype. This is the first reported case of extreme gestational hyperlipidemia with a partial LPL deficiency in the absence of an LPL gene mutation and the apolipoprotein E 3/2 genotype. She was managed with strict dietary control and medicated with omega-3 acid ethyl esters. A patient with extreme hyperlipidemia that is limited to the gestational period should be considered partially LPL-deficient. Extreme instances of hyperlipidemia increase the risk of acute pancreatitis, and the effect of parturition on declining plasma lipid levels can be immediate and dramatic. Therefore, decisions regarding the timing and route of delivery with extreme gestational hyperlipidemia are critical and should be made carefully.
Acute Disease
;
Adult
;
Apolipoprotein E2/*genetics
;
Apolipoprotein E3/*genetics
;
Biological Markers/blood
;
Combined Modality Therapy
;
Diet, Fat-Restricted
;
Fatty Acids, Omega-3/therapeutic use
;
Female
;
Fluid Therapy
;
Genetic Predisposition to Disease
;
Humans
;
Hyperlipoproteinemia Type I/blood/diagnosis/enzymology/*genetics/therapy
;
Lipids/blood
;
Lipoprotein Lipase/genetics
;
Pancreatitis/diagnosis/*etiology/therapy
;
Parenteral Nutrition, Total
;
Phenotype
;
Pregnancy
;
Pregnancy Complications/blood/diagnosis/enzymology/*genetics/therapy
;
Recurrence
;
Tomography, X-Ray Computed
;
Treatment Outcome